Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-05-28FDA Approved: XULTOPHY 100/3.6 — Supplemental Application (Novo Nordisk)
FDA approved a supplemental application for XULTOPHY 100/3.6 (insulin degludec and liraglutide) from Novo Nordisk.
-
FDA approval · 2025-05-28FDA Approved: TRULICITY — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Trulicity (dulaglutide) from Eli Lilly and Company. This action completes regulatory approva…
-
FDA approval · 2025-05-28FDA Approved: SOLIQUA 100/33 — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approved a supplemental application for SOLIQUA 100/33 (insulin glargine and lixisenatide) from Sanofi-Aventis U.S. LLC.
-
EMA approval · 2025-05-23EMA Authorised: Komboglyze (metformin hydrochloride;saxagliptin hydrochloride) — AstraZeneca AB
EMA authorised Komboglyze, a fixed-dose combination of metformin hydrochloride and saxagliptin hydrochloride for type 2 diabetes mellitus, m…
-
EMA approval · 2025-05-19EMA Authorised: Vipdomet (alogliptin benzoate;metformin hydrochloride) — Takeda Pharma A/S
European Medicines Agency authorised Vipdomet, a fixed-dose combination of alogliptin benzoate and metformin hydrochloride, for the treatmen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-05-13FDA Approved: PIOGLITAZONE AND METFORMIN HYDROCHLORIDE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for Macleods Pharmaceuticals Limited to market Pioglitazone and Metformin Hydrochloride as a fix…
-
FDA approval · 2025-05-07FDA Approved: INSULIN LISPRO — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for insulin lispro from Eli Lilly and Company.
-
EMA approval · 2025-05-06EMA Authorised: Sitagliptin / Metformin hydrochloride Sun (sitagliptin fumarate;metformin hydrochloride) — Sun Pharmaceutical Industries Europe B.V.
EMA authorised Sun Pharmaceutical's fixed-dose combination of sitagliptin fumarate and metformin hydrochloride for type 2 diabetes mellitus.
-
FDA approval · 2025-05-06FDA Approved: GLIMEPIRIDE — Supplemental Application (Solco Healthcare U.S., LLC)
The FDA approved a supplemental application for glimepiride, enabling Solco Healthcare U.S., LLC to market a generic version of this diabete…
-
FDA approval · 2025-04-22FDA Approved: COLESEVELAM HYDROCHLORIDE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for Colesevelam hydrochloride (generic) submitted by Bionpharma Inc., effectively granting approval …
-
FDA approval · 2025-04-14FDA Approved: METFORMIN HYDROCHLORIDE ORAL SOLUTION — Original Application (Bionpharma Inc.,)
FDA approved METFORMIN HYDROCHLORIDE ORAL SOLUTION from Bionpharma Inc. under an Original Application (ANDA 219151).
-
EMA approval · 2025-04-09EMA Authorised: Competact (pioglitazone;metformin hydrochloride) — CHEPLAPHARM Arzneimittel GmbH
The EMA authorised Competact, a fixed-dose combination of pioglitazone and metformin, for the treatment of type 2 diabetes mellitus, with CH…
-
FDA approval · 2025-04-02FDA Approved: LIRAGLUTIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved the original application for liraglutide (Meitheal Pharmaceuticals Inc.), enabling marketing of a liraglutide injection in the …
-
FDA approval · 2025-03-24FDA Approved: METFORMIN HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for METFORMIN HYDROCHLORIDE granules from Granules Pharmaceuticals Inc., allowing its generic produc…
-
FDA approval · 2025-03-13FDA Approved: METFORMIN HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' metformin hydrochloride as an original ANDA, providing a generic treatment option for type 2 diabetes m…
-
FDA approval · 2025-03-07FDA Approved: SYNJARDY — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for SYNJARDY, a combination of empagliflozin and metformin hydrochloride, submitted by Boehringer In…
-
EMA approval · 2025-02-19EMA Authorised: Galvus (vildagliptin) — Novartis Europharm Limited
The European Medicines Agency authorised the diabetes medicine Galvus (vildagliptin) for use in the EU, with Novartis Europharm Limited as t…
-
EMA approval · 2025-02-11EMA Authorised: Repaglinide Teva (repaglinide) — Teva Pharma B.V.
The EMA has authorised Repaglinide Teva (repaglinide) for the treatment of type 2 diabetes mellitus, with Teva Pharma B.V. as the marketing …
-
EMA approval · 2025-02-05EMA Authorised: Enyglid (repaglinide) — Krka, d.d., Novo mesto
Enyglid (repaglinide) by Krka has been authorized in the EU for the treatment of type 2 diabetes mellitus.
-
EMA approval · 2025-02-04EMA Authorised: Repaglinide Krka (repaglinide) — Krka, d.d., Novo mesto
The EMA authorised Repaglinide Krka for Type 2 diabetes mellitus. The product is a generic repaglinide from Krka, d.d., Novo mesto.
-
FDA approval · 2025-01-28FDA Approved: OZEMPIC — Supplemental Application (Novo Nordisk)
The FDA approved a supplemental application for Ozempic (semaglutide) from Novo Nordisk, updating the product label following the submission…
-
EMA approval · 2025-01-27EMA Authorised: Sitagliptin Accord (sitagliptin hydrochloride) — Accord Healthcare S.L.U.
The European Medicines Agency authorised Sitagliptin Accord (sitagliptin hydrochloride) for the treatment of type 2 diabetes mellitus; the p…
-
FDA approval · 2025-01-16FDA Approved: BRYNOVIN — Original Application (Azurity Pharmaceuticals, Inc.)
The FDA approved Brynovin as an original-application product containing sitagliptin hydrochloride for oral use, for the treatment of type 2 …
-
FDA approval · 2024-12-23FDA Approved: LIRAGLUTIDE — Original Application (Hybio Pharmaceutical Co., Ltd. (Pingshan Factory))
FDA approved an original application for liraglutide manufactured by Hybio Pharmaceutical Co., Ltd. (Pingshan Factory).
-
FDA approval · 2024-12-20FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dapagliflozin and metformin hydrochloride, enabling a fixed-dose combination product for type 2 …